Literature DB >> 10451705

Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors.

C M Hattinger1, S Rumpler, S Strehl, I M Ambros, A Zoubek, U Pötschger, H Gadner, P F Ambros.   

Abstract

Ewing's sarcoma, peripheral primitive neuroectodermal tumors, and Askin tumors are referred to as Ewing tumors (ETs), and are characterized by high MIC2 expression and a t(11;22)(q24;q12) or other rearrangements involving 22q12. In addition to these constant aberrations, facultative numerical and structural aberrations have been reported: gains of chromosomes 8 and 12, the unbalanced translocation t(1;16), and deletions at the short arm of chromosome 1. To evaluate the frequency and to study the biological impact of these facultative aberrations, we analyzed tumor specimens from 58 ET patients by classical cytogenetics and/or in situ hybridization techniques and compared these data with clinical parameters. Gains of chromosomes 8 and 12 were detected in 55% (32/58) and 24% (14/58) of the cases, respectively. Loss of chromosome 16 or der (16)t(1;16) chromosomes were found in 20% (10/51); deletions at 1p36 were observed in 18% (9/51) of the cases evaluated. The presence of these aberrations did not correlate with age and sex of the patients, with the location of the primary tumor or with the extent of disease at diagnosis by chi-square analysis and Fisher's exact test. Patients with tumors harboring gains of chromosome 8 showed a slightly better clinical outcome (n = 14/30, P = 0.17), whereas gains of chromosome 12 did not influence the clinical outcome (n = 7/30, P = 0.63). However, Kaplan and Meier analysis revealed that deletions at the short arm of chromosome 1 were associated with an unfavorable outcome in patients with localized disease (n = 6/22; P = 0.004).

Entities:  

Mesh:

Year:  1999        PMID: 10451705     DOI: 10.1002/(sici)1098-2264(199903)24:3<243::aid-gcc10>3.0.co;2-a

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  13 in total

1.  Inconspicuous insertion 22;12 in myxoid/round cell liposarcoma accompanied by the secondary structural abnormality der(16)t(1;16).

Authors:  Nathan C Birch; Cristina R Antonescu; Marilu Nelson; Lisa Sarran; James R Neff; Thomas Seemayer; Julia A Bridge
Journal:  J Mol Diagn       Date:  2003-08       Impact factor: 5.568

2.  Ewing's sarcoma metastasis to the gastric wall in a 72-year-old patient.

Authors:  Laura Borodyansky Dodis; Michael William Bennett; David L Carr-Locke
Journal:  MedGenMed       Date:  2006-07-10

3.  Targeted next-generation sequencing of CIC-DUX4 soft tissue sarcomas demonstrates low mutational burden and recurrent chromosome 1p loss.

Authors:  Lorena Lazo de la Vega; Daniel H Hovelson; Andi K Cani; Chia-Jen Liu; Jonathan B McHugh; David R Lucas; Dafydd G Thomas; Rajiv M Patel; Scott A Tomlins
Journal:  Hum Pathol       Date:  2016-09-21       Impact factor: 3.466

4.  Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization.

Authors:  Cornelia Stock; Eva Bozsaky; Franz Watzinger; Ulrike Poetschger; Lukas Orel; Thomas Lion; Agata Kowalska; Peter F Ambros
Journal:  Am J Pathol       Date:  2007-12-28       Impact factor: 4.307

Review 5.  Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities.

Authors:  S A Burchill
Journal:  J Clin Pathol       Date:  2003-02       Impact factor: 3.411

6.  Adult primary pulmonary primitive neuroectodermal tumor: molecular features and translational opportunities.

Authors:  Mirela Andrei; Stewart F Cramer; Zachary B Kramer; Amer Zeidan; Bishoy Faltas
Journal:  Cancer Biol Ther       Date:  2012-10-31       Impact factor: 4.742

Review 7.  Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?

Authors:  Elizabeth R Lawlor; Poul H Sorensen
Journal:  Crit Rev Oncog       Date:  2015

8.  An integrated analysis of miRNA and gene copy numbers in xenografts of Ewing's sarcoma.

Authors:  Neda Mosakhani; Mohamed Guled; Gayle Leen; Silvia Calabuig-Fariñas; Tarja Niini; Isidro Machado; Suvi Savola; Katia Scotlandi; José Antonio López-Guerrero; Antonio Llombart-Bosch; Sakari Knuutila
Journal:  J Exp Clin Cancer Res       Date:  2012-03-20

9.  Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.

Authors:  Neerav Shukla; Joshua Schiffman; Damon Reed; Ian J Davis; Richard B Womer; Stephen L Lessnick; Elizabeth R Lawlor
Journal:  Front Oncol       Date:  2013-06-06       Impact factor: 6.244

10.  The clinical use of biomarkers as prognostic factors in Ewing sarcoma.

Authors:  Annmeik M van Maldegem; Pancras Cw Hogendoorn; Andrew B Hassan
Journal:  Clin Sarcoma Res       Date:  2012-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.